- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01797601
Insulin Sensitivity of the Human CNS System: fMRI Study With Intranasal Insulin Application
December 2, 2015 updated by: andreas fritsche, University Hospital Tuebingen
Insulinsensitivität Des Menschlichen Zentralnervensystems: Kernspintomographische Untersuchung Mit Intranasaler Gabe Von Insulin
The purpose of the study is to investigate whether insulin sensitivity and insulin resistance of the human brain is comparable in all insulin sensitive parts of the brain and whether correlates to other phenotypic information (i.e.
whole body insulin sensitivity, BMI, age) of the study participants.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tuebingen, Germany, 72074
- University of Tuebingen
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Normal routine blood works
- for women: negative pregnancy test
- healthy
Exclusion Criteria:
- Type 2 diabetes
- pregnancy
- acute or chronic diseases
- Pacemakers
- Artificial heart valves
- Metal prostheses
- Implanted magnetic metal parts (screws, ...)
- Metal fragments
- Braces
- insulin pumps
- Tattoos
- claustrophobia
- reduced temperature sensation and / or increased sensitivity to warming of the body
- Ear disease or an increased sensitivity to loud noises
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Human Insulin
Nasal spray
|
160 U of insulin
|
|
Placebo Comparator: Placebo solution
Nasal spray
|
Insulin dilution medium without insulin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Insulin effect on regional brain activity assessed by fMRI
Time Frame: Change from Baseline to 15 minutes and 60 minutes post spray application
|
Change from Baseline to 15 minutes and 60 minutes post spray application
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Andreas Fritsche, MD, Universitat Tubingen
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2013
Primary Completion (Actual)
April 1, 2014
Study Completion (Actual)
April 1, 2014
Study Registration Dates
First Submitted
February 18, 2013
First Submitted That Met QC Criteria
February 20, 2013
First Posted (Estimate)
February 22, 2013
Study Record Updates
Last Update Posted (Estimate)
December 3, 2015
Last Update Submitted That Met QC Criteria
December 2, 2015
Last Verified
December 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Eudra-CT: 2006-002244-29
- 17/2008AMG1 (Other Identifier: Ethik-Kommission an der Medizinischen Fakultät der Eberhard-Karls-Universität und am Universitätsklinikum Tübingen)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical ConditionsUnited States
-
Central Hospital, Nancy, FranceNot yet recruiting
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation TechniquesUnited States
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsCompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
Clinical Trials on Human Insulin
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1Indonesia
-
Université NAZI BONIJuvenile Diabetes Research Foundation; International Society for Pediatric... and other collaboratorsCompletedType 1 DiabetesBurkina Faso
-
Eli Lilly and CompanyCompletedDiabetes Mellitus, Type 2 | Acute Myocardial InfarctionCanada, Croatia, Czech Republic, Germany, Hungary, India, Israel, Lebanon, Poland, Romania, Russian Federation, Slovakia, Slovenia, South Africa, Spain, Turkey, United Kingdom
-
Novo Nordisk A/SCompletedDiabetes | Diabetes Mellitus, Type 1Sweden
-
Aristotle University Of ThessalonikiUniversity Hospital TuebingenCompletedDiabetes Mellitus, Type 2
-
Novo Nordisk A/SCompletedDiabetes | Diabetes Mellitus, Type 1Germany
-
Zhuhai United Laboratories Co., Ltd.CompletedPharmacokinetics and PharmacodynamicsChina
-
Lise TarnowNovo Nordisk A/SCompleted
-
Novo Nordisk A/SCompletedDiabetes | Diabetes Mellitus, Type 1Croatia, Italy, Slovakia, Denmark, Macedonia, The Former Yugoslav Republic of, Norway, Russian Federation, Finland, France, Poland, Greece, Romania, Sweden, Czech Republic, Argentina
-
Nastech Pharmaceutical Company, Inc.CompletedDiabetes MellitusUnited States